{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05732194",
            "orgStudyIdInfo": {
                "id": "ITI-333-002"
            },
            "secondaryIdInfos": [
                {
                    "id": "1UG3DA047699-02",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1UG3DA047699-02"
                }
            ],
            "organization": {
                "fullName": "Intra-Cellular Therapies, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ITI-333 in Healthy Subjects",
            "therapeuticArea": [
                "Other"
            ],
            "study": "multiple-ascending-dose-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-iti-in-healthy-volunteers"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-07",
            "studyFirstSubmitQcDate": "2023-02-07",
            "studyFirstPostDateStruct": {
                "date": "2023-02-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-03-02",
            "lastUpdatePostDateStruct": {
                "date": "2023-03-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Intra-Cellular Therapies, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study will be conducted as a single-center, randomized, double-blind, placebo-controlled, ascending dose study in up to 4 sequential cohorts of healthy subjects. Each cohort will enroll 8 subjects: 6 subjects will receive ITI-333 and 2 subjects will receive placebo once daily for 14 days."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Sequential ascending doses. Parallel (active, placebo) within each cohort",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: 0.75 mg ITI-333 or placebo once daily for 14 days",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-333",
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "Cohort 2: 1.5 mg ITI-333 or placebo once daily for 14 days",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-333",
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "Cohort 3: 3 mg ITI-333 or placebo once daily for 14 days",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-333",
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "Cohort 4: 6 mg ITI-333 or placebo once daily for 14 days",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-333",
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ITI-333",
                    "description": "ITI-333 oral solution",
                    "armGroupLabels": [
                        "Cohort 1: 0.75 mg ITI-333 or placebo once daily for 14 days",
                        "Cohort 2: 1.5 mg ITI-333 or placebo once daily for 14 days",
                        "Cohort 3: 3 mg ITI-333 or placebo once daily for 14 days",
                        "Cohort 4: 6 mg ITI-333 or placebo once daily for 14 days"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Matching placebo",
                    "armGroupLabels": [
                        "Cohort 1: 0.75 mg ITI-333 or placebo once daily for 14 days",
                        "Cohort 2: 1.5 mg ITI-333 or placebo once daily for 14 days",
                        "Cohort 3: 3 mg ITI-333 or placebo once daily for 14 days",
                        "Cohort 4: 6 mg ITI-333 or placebo once daily for 14 days"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacokinetics: AUC0-tau",
                    "description": "Area under the plasma drug concentration-time curve (AUC) from time zero to the end of dosing interval",
                    "timeFrame": "predose and multiple timepoints up to 24 hours postdose on Days 1 and 14"
                },
                {
                    "measure": "Pharmacokinetics: Cmax",
                    "description": "Maximum plasma concentration of ITI-333 and its metabolites over a dosing interval",
                    "timeFrame": "predose and multiple timepoints up to 24 and 72 hours postdose on Days 1 and 14, respectively"
                },
                {
                    "measure": "Pharmacokinetics: Tmax",
                    "description": "Time of maximum plasma concentration of ITI-333 and its metabolites over a dosing interval",
                    "timeFrame": "predose and multiple timepoints up to 24 and 72 hours postdose on Days 1 and 14, respectively"
                },
                {
                    "measure": "Percentage of subjects with treatment-emergent adverse events",
                    "timeFrame": "up to 30 days after last dose"
                },
                {
                    "measure": "Change from baseline in systolic and diastolic blood pressure",
                    "timeFrame": "Up to Day 24"
                },
                {
                    "measure": "Change from baseline in SpO2",
                    "timeFrame": "Up to Day 24"
                },
                {
                    "measure": "Change from baseline in ECG QT interval",
                    "timeFrame": "Up to Day 24"
                },
                {
                    "measure": "Change from baseline in aspartate aminotransferase",
                    "timeFrame": "Up to Day 24"
                },
                {
                    "measure": "Change from baseline in alanine aminotransferase",
                    "timeFrame": "Up to Day 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Healthy male and female subjects between 18 and 45 years old (inclusive);\n* BMI inclusive of 18-32 kg/m2 at screening and a minimum weight of 50 kg;\n* Willingness to remain in the clinic for the inpatient portion of the study and return for follow-up visit(s) as required by protocol and as deemed necessary by the Investigator.\n\nKey Exclusion Criteria:\n\n* Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the subject at risk or interfere with study outcome variables; this includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, GI, pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy;\n* Clinically significant abnormal findings in vital sign assessments, including blood oxygen saturation (SpO2) \\< 96% and respiratory rate \\< 12 breaths per min;\n* History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study;\n* CRP, ESR, or fibrinogen that are above normal reference ranges at Screening or Day 1.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ITI Clinical Trials",
                    "role": "CONTACT",
                    "phone": "646 440-9333",
                    "email": "ITCIClinicalTrials@itci-inc.com"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Site 1",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33014-3616",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}